
Pharmacists Association warns FDA against premature peptide approval
The American Pharmacists Association is pushing the FDA to reject the inclusion of several peptide substances on the Section 503A Bulks List, citing a lack of clinical evidence. The organization warns that current unregulated online markets for these substances pose severe risks, including contamination and inaccurate dosing for unsuspecting patients.























